Alzamend Neuro, INC. (ALZN) — 10-K Filings
All 10-K filings from Alzamend Neuro, INC.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Alzamend Neuro Continues R&D Focus, Zero Revenue in FY25
— Jul 22, 2025 Risk: high
Alzamend Neuro, Inc. reported no revenue for the fiscal year ended April 30, 2025, consistent with its pre-commercial stage as a pharmaceutical company. The net -
Alzamend Neuro Files 2024 10-K
— Jul 30, 2024 Risk: medium
Alzamend Neuro, Inc. filed its 10-K for the fiscal year ending April 30, 2024, reporting on its operations and financial condition. The company is focused on th
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX